| Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice C Müller, M Bunka, S Haller, U Köster, V Groehn, P Bernhardt, ... Journal of nuclear medicine 55 (10), 1658-1664, 2014 | 202 | 2014 |
| 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 CA Umbricht, M Benešová, RM Schmid, A Türler, R Schibli, ... EJNMMI research 7, 1-10, 2017 | 189 | 2017 |
| Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application C Müller, KA Domnanich, CA Umbricht, NP van der Meulen The British journal of radiology 91 (1091), 20180074, 2018 | 155 | 2018 |
| Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer C Müller, CA Umbricht, N Gracheva, VJ Tschan, G Pellegrini, P Bernhardt, ... European journal of nuclear medicine and molecular imaging 46, 1919-1930, 2019 | 153 | 2019 |
| Cyclotron production of 44Sc: from bench to bedside NP van der Meulen, M Bunka, KA Domnanich, C Müller, S Haller, ... Nuclear medicine and biology 42 (9), 745-751, 2015 | 118 | 2015 |
| Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics C Müller, C Vermeulen, U Köster, K Johnston, A Türler, R Schibli, ... EJNMMI radiopharmacy and chemistry 1, 1-5, 2017 | 110 | 2017 |
| Future prospects for SPECT imaging using the radiolanthanide terbium-155—production and preclinical evaluation in tumor-bearing mice C Müller, E Fischer, M Behe, U Köster, H Dorrer, J Reber, S Haller, ... Nuclear medicine and biology 41, e58-e65, 2014 | 84 | 2014 |
| 47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes KA Domnanich, C Müller, M Benešová, R Dressler, S Haller, U Köster, ... EJNMMI Radiopharmacy and Chemistry 2, 1-17, 2017 | 81 | 2017 |
| Measurement of 43Sc and 44Sc production cross-section with an 18 MeV medical PET cyclotron TS Carzaniga, M Auger, S Braccini, M Bunka, A Ereditato, KP Nesteruk, ... Applied radiation and isotopes 129, 96-102, 2017 | 77 | 2017 |
| First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study A Singh, NP van der Meulen, C Müller, I Klette, HR Kulkarni, A Türler, ... Cancer Biotherapy and Radiopharmaceuticals 32 (4), 124-132, 2017 | 77 | 2017 |
| Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152 Tb-DOTATOC RP Baum, A Singh, M Benešová, C Vermeulen, S Gnesin, U Köster, ... Dalton transactions 46 (42), 14638-14646, 2017 | 77 | 2017 |
| Investigation of the 66Zn (p, 2pn) 64Cu and 68Zn (p, x) 64Cu nuclear processes up to 100 MeV: Production of 64Cu F Szelecsényi, GF Steyn, Z Kovács, C Vermeulen, NP Van Der Meulen, ... Nuclear Instruments and Methods in Physics Research Section B: Beam …, 2005 | 74 | 2005 |
| Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy N Gracheva, C Müller, Z Talip, S Heinitz, U Köster, JR Zeevaart, A Vögele, ... EJNMMI radiopharmacy and chemistry 4, 1-16, 2019 | 73 | 2019 |
| 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations KA Domnanich, C Müller, R Farkas, RM Schmid, B Ponsard, R Schibli, ... EJNMMI Radiopharmacy and Chemistry 1, 1-19, 2017 | 68 | 2017 |
| Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate S Haller, G Pellegrini, C Vermeulen, NP van der Meulen, U Köster, ... EJNMMI research 6, 1-11, 2016 | 65 | 2016 |
| Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617 CA Umbricht, U Köster, P Bernhardt, N Gracheva, K Johnston, R Schibli, ... Scientific reports 9 (1), 17800, 2019 | 59 | 2019 |
| Radiometals for imaging and theranostics, current production, and future perspectives R Mikolajczak, NP van der Meulen, SE Lapi Journal of Labelled Compounds and Radiopharmaceuticals 62 (10), 615-634, 2019 | 57 | 2019 |
| Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising α-particle, β−-particle, and auger electron emitters C Müller, NP van der Meulen, M Benešová, R Schibli Journal of Nuclear Medicine 58 (Supplement 2), 91S-96S, 2017 | 57 | 2017 |
| Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising α-particle, β−-particle, and auger electron emitters C Müller, NP van der Meulen, M Benešová, R Schibli Journal of Nuclear Medicine 58 (Supplement 2), 91S-96S, 2017 | 57 | 2017 |
| Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging C Müller, C Vermeulen, K Johnston, U Köster, R Schmid, A Türler, ... EJNMMI research 6, 1-10, 2016 | 57 | 2016 |
Cristina MuellerResearch Group Leader at the Center for Radiopharmaceutical Sciences, Paul Scherrer InstituteVerified email at psi.ch
